Gouaze et al. [25] suggested that GCS blockade resensitizes MDR breast cancer cells to anticancer drugs via downregulation of MDR1. Liu et al. [26] further demonstrated that GCS upregulates MDR1 expressions through cSrc and beta-catein signaling. The gene discussed is UGCG; the disease is breast carcinoma.